Summary: In a small three-arm trial in refractory diabetic erectile dysfunction, combining placenta-derived mesenchymal stem cells with low-intensity shock wave therapy outperformed either treatment alone at 6 months for erection duration and penile hardness, with no severe adverse events.
PICO Summary
| Element | Detail |
|---|---|
| Population | 33 men with refractory diabetic erectile dysfunction (1:1:1 randomisation). |
| Intervention | High-activity placenta-derived mesenchymal stem cells (hPMSCs) plus low-intensity extracorporeal shock wave therapy (LI-ESWT). |
| Comparison | hPMSCs alone or LI-ESWT alone. |
| Outcome | At 6 months the combined group had superior total erection time (22.20 min; p=0.001) and full erection time (11.90 min; p=0.004), with 70% achieving Erection Hardness Score >2 (p=0.045). No severe adverse events; mild local pain resolved within a week. |
Stem cells + shock wave therapy for diabetic ED
RCT · refractory diabetic ED · 6 months
Combining hPMSCs with LI-ESWT improved erection duration and penile hardness more than either alone at 6 months, with no severe adverse events. A small proof-of-concept signal, not standard care.
Expert Commentary
Diabetic erectile dysfunction is genuinely hard to treat, with up to half of men responding poorly to PDE5 inhibitors, so regenerative approaches that target the underlying nerve and vascular damage are a reasonable avenue, and the synergy hypothesis here, shock-wave priming the tissue for stem-cell engraftment, is mechanistically coherent. But this is where I have to be disciplined rather than enthusiastic. With only 33 men across three arms, roughly eleven per group, and six-month follow-up, this is a small proof-of-concept study, and the eye-catching erection-time figures rest on tiny numbers with wide uncertainty. Stem-cell products also vary enormously in quality, the long-term safety of cell therapies needs ongoing surveillance, and durability beyond six months is unknown. Can I use this with my patients? No, not as a treatment I would offer or endorse. What I would do is use it to counsel honestly: regenerative ED therapy is an early, promising research direction, not standard care, and any patient drawn to it should be steered toward a reputable clinical trial rather than a commercial stem-cell clinic, while we optimise glycaemic control and continue established options. Larger, longer, multicentre trials are essential before this means anything clinically.
References
Ji YH, Zhang YF, Tan X, Hou HZ, Yao Z, Zhang B. High-activity placenta-derived mesenchymal stem cells combined with low-intensity extracorporeal shock wave therapy for diabetic erectile dysfunction: a prospective randomized controlled trial. Stem Cell Res Ther. 2025;16(1):359. doi:10.1186/s13287-025-04499-9